Augmedix (AUGX)
(Delayed Data from NSDQ)
$2.33 USD
+0.01 (0.43%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.33 USD
+0.01 (0.43%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Zacks News
Is Augmedix (AUGX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is Augmedix (AUGX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Augmedix, Inc. (AUGX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Augmedix, Inc. (AUGX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Augmedix, Inc. (AUGX) delivered earnings and revenue surprises of 6.67% and 2.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of 15% and 1.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 21.05% and 7.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 48.39% and 3.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?